全文获取类型
收费全文 | 32137篇 |
免费 | 2481篇 |
国内免费 | 51篇 |
专业分类
耳鼻咽喉 | 230篇 |
儿科学 | 1130篇 |
妇产科学 | 873篇 |
基础医学 | 4207篇 |
口腔科学 | 344篇 |
临床医学 | 4872篇 |
内科学 | 5911篇 |
皮肤病学 | 396篇 |
神经病学 | 3060篇 |
特种医学 | 874篇 |
外科学 | 2910篇 |
综合类 | 422篇 |
一般理论 | 74篇 |
预防医学 | 4454篇 |
眼科学 | 499篇 |
药学 | 1959篇 |
1篇 | |
中国医学 | 28篇 |
肿瘤学 | 2425篇 |
出版年
2023年 | 123篇 |
2022年 | 201篇 |
2021年 | 514篇 |
2020年 | 350篇 |
2019年 | 554篇 |
2018年 | 662篇 |
2017年 | 520篇 |
2016年 | 551篇 |
2015年 | 596篇 |
2014年 | 927篇 |
2013年 | 1447篇 |
2012年 | 2124篇 |
2011年 | 2193篇 |
2010年 | 1212篇 |
2009年 | 1046篇 |
2008年 | 2059篇 |
2007年 | 2182篇 |
2006年 | 2139篇 |
2005年 | 2155篇 |
2004年 | 2058篇 |
2003年 | 1923篇 |
2002年 | 1773篇 |
2001年 | 410篇 |
2000年 | 353篇 |
1999年 | 442篇 |
1998年 | 432篇 |
1997年 | 314篇 |
1996年 | 312篇 |
1995年 | 285篇 |
1994年 | 263篇 |
1993年 | 228篇 |
1992年 | 295篇 |
1991年 | 277篇 |
1990年 | 256篇 |
1989年 | 263篇 |
1988年 | 221篇 |
1987年 | 218篇 |
1986年 | 219篇 |
1985年 | 226篇 |
1984年 | 177篇 |
1983年 | 210篇 |
1982年 | 188篇 |
1981年 | 172篇 |
1980年 | 178篇 |
1979年 | 139篇 |
1978年 | 117篇 |
1977年 | 125篇 |
1976年 | 118篇 |
1975年 | 112篇 |
1974年 | 112篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
Andrea DiMartini Nancy Day Mary Amanda Dew Lubna Javed Mary Grace Fitzgerald Ashok Jain John J Fung Paulo Fontes 《Liver transplantation》2006,12(5):813-820
For patients who receive a liver transplant (LTX) for alcoholic liver disease (ALD), investigators are focusing beyond survival to determine specific alcohol use outcomes. Studies suggest the use of alcohol ranges from 8 to 22% for the first post-transplant year with cumulative rates reaching 30 to 40% by 5 years following transplantation. Yet while investigators are interested in determining specific rates of alcohol use and predictors of use, only three studies since 1990 have been prospective. In 1998, we began a prospective study of post-LTX alcohol consumption in ALD recipients using multiple repeated measures of alcohol use. After 5 years of follow-up, we found that 22% had used any alcohol by the first year and 42% had a drink by 5 years. By 5 years, 26% drank at a heavier use (binge) pattern and 20% drank in a frequent pattern. In a univariate model, predictors of alcohol use included pre-transplant length of sobriety, a diagnosis of alcohol dependence, a history of other substance use, and prior alcohol rehabilitation. 相似文献
12.
Severe persistent asthma can have a substantial impact on a patient's health-related quality of life (HRQL), both as a result of symptoms and from side effects of treatment. The HRQL impact of two doses (400 and 800 microg twice daily) of mometasone furoate dry powder inhaler (MF DPI) was compared with placebo in patients with severe persistent asthma previously maintained on oral steroids as a component of a previously published randomized, 12-week, double-blind, placebo-controlled, multicenter trial. A 9-month open-label extension (OLE), with all patients treated with MF DPI, followed. Patients 12 years of age or older completed a generic HRQL measure, the Medical Outcomes Trust Short Form-36 (SF-36), and an asthma-specific measure, the Marks Asthma Quality of Life Questionnaire (AQLQ-M), at baseline, at endpoint (last evaluable visit) of the double-blind phase (EODBP), and after the first 3 months of the OLE. Of 132 patients enrolled in the study, 128 provided HRQL data at baseline and at EODBP. Mean SF-36 scores at baseline showed significant HRQL impairment compared with U.S. general population norms. With treatment, the reduction in oral corticosteroid (OCS) requirements of the MF-DPI-treated groups was accompanied by significant (p < 0.05) improvement over placebo in the physical domain of HRQL (SF-36 physical component summary score and the physical function subscale) at EODBP. MF-DPI-treated patients also showed significant improvements at EODBP in each of the four subscales of the AQLQ-M (p<0.05). From EODBP to the OLE 3-month endpoint, patients treated with MF DPI twice daily maintained, or improved, SF-36 scores in most domains. Symptomatic improvement and reduction in OCS use with MF DPI were accompanied by significant improvement in HRQL in patients with severe persistent asthma. These improvements were maintained during the 3-month period of the OLE in which HRQL was evaluated. 相似文献
13.
14.
K P Sylvester S R Desai A U Wells D M Hansell M Awogbade S L Thein A Greenough 《The European respiratory journal》2006,28(4):832-838
The aim of this study was to determine whether patients with sickle cell disease (SCD) in steady state had pulmonary abnormalities seen on high-resolution computed tomography (HRCT) and whether any abnormalities correlated with contemporaneously diagnosed lung function abnormalities. A subsidiary question was whether the results of a noninvasive measure of haemolysis (end-tidal carbon monoxide (ETCO) levels) correlated with pulmonary function abnormalities. Thirty three patients with SCD, median (range) age 36 yrs (17-67 yrs) were examined. The degree of lobar volume loss and ground-glass opacification and prominence of central vessels on HRCT were quantitatively assessed. Pulmonary function was assessed by measurements of lung volumes, spirometry, gas transfer and oxygen saturation. ETCO levels were measured using an end-tidal CO monitor. Forced expiratory volume in one second (FEV1), forced vital capacity and total lung capacity significantly correlated with HRCT findings, particularly lobar volume loss. ETCO levels significantly negatively correlated with FEV1, vital capacity measured using a plethysmograph, specific airway conductance and arterial oxygen saturation measured by pulse oxymetry. In conclusion, the present results suggest that high-resolution computed tomography noninvasive assessment of haemolysis might be useful to identify sickle cell disease patients with respiratory function impairment. 相似文献
15.
Tony R Cucuzzella Elva G Delport Nancy Kim Julie Marley Christine Pruitt Anton G Delport 《The spine journal》2006,6(4):364-369
BACKGROUND CONTEXT: Substantial variation exists regarding the use of sedation before interventional spine techniques. Patient preference should play an important role in decision making regarding the need for sedation. However, little is known about patients' anxiety levels before spinal injections and their perceptions about the necessity of sedation. PURPOSE: To determine patient perception for need for sedation before epidural steroid injections and zygapophyseal joint injections. STUDY DESIGN/SETTING: Survey of consecutive spinal injection patients in an outpatient spine center. PATIENT SAMPLE: 500 consecutive lumbar, thoracic, and cervical patients receiving spinal injections. OUTCOME MEASURES: A 12-item questionnaire assessing patients' perceived anxiety before to a spinal injection. METHODS: Subjects were given the questionnaire after their spinal injection. Percentages requesting sedation for a first and potential second procedure were assessed. Additionally, anxiety level and pain rating, location of injection, age, sex, and other medication use were analyzed to determine the effect on the request for sedation. RESULTS: 17% of patients questioned requested sedation before an injection, and 28% would request sedation if they were to have a second injection. CONCLUSIONS: Routine sedation before diagnostic and therapeutic injections is not necessary as the majority of patients would not request sedation before the procedure when given the option. However, in some patients sedation is indicated, and all patients would benefit from educational material on sedation before the injection. 相似文献
16.
17.
18.
Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation 总被引:2,自引:0,他引:2
Rolf N. Barth Christina A. Janus Christine A. Lillesand Nancy A. Radke John D. Pirsch Bryan N. Becker Luis A. Fernandez L. Thomas Chin Yolanda T. Becker Jon S. Odorico Anthony M. D''Alessandro Hans W. Sollinger Stuart J. Knechtle 《Transplant international》2006,19(11):885-892
Campath-1H (alemtuzumab) induction was used for renal transplantation in combination with sirolimus as immunosuppression. We previously reported a high (28%) rate of early rejection with this regimen, and now report 3-year outcomes. Twenty-nine patients were recipients of either deceased donor or non-HLA (Human Leukocyte Antigen) identical living donor primary renal allografts. Clinical parameters including infection, malignancy, kidney function, and kidney histology were followed prospectively for 3 years. Three-year cumulative graft and patient survival were 96% and 100%, respectively. Twenty patients were maintained on steroid-free immunosuppressive regimens, and 15 patients were maintained on monotherapy for immunosuppression (12 on sirolimus). No serious infectious complications were observed and two patients developed basal cell skin cancer. The 3-year results of our initial pilot study demonstrate good graft (96%) and patient (100%) outcomes. Campath-1H induction has yielded a high proportion of patients maintained on immunosuppressive monotherapy (57%) without serious infectious- and no malignancy-related complications. The reported regimen yielded novel insights into both Campath-1H and sirolimus therapy in renal transplantation. Because of the higher incidence of early rejection, we recommend a modified strategy of immunosuppression including a brief course of a calcineurin inhibitor. 相似文献
19.
20.